Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue European Journal of Haematology Année : 2019

Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone

Résumé

Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
Fichier principal
Vignette du fichier
Revised Manuscript VRD EJH Final version.pdf (197.23 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02267221 , version 1 (18-10-2019)

Identifiants

Citer

Robin Arcani, Geoffroy Venton, Julien Colle, Pierre Suchon, Vadim Ivanov, et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, 2019, ⟨10.1111/ejh.13297⟩. ⟨hal-02267221⟩

Collections

INSERM UNIV-AMU
94 Consultations
367 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More